Her son was dying, but his rare cancer made it difficult to get the right drug

Key Points:

• Mason Henderson, a 21-year-old with a rare brain tumor called diffuse hemispheric glioma, faced limited treatment options and insurance denials after standard chemotherapy and a clinical trial failed to stop his cancer's progression.
• His doctors prescribed Lynparza, a drug targeting specific tumor genetics, but his insurance and pharmacy benefit manager refused coverage since the drug was not FDA-approved for his cancer type, leaving the family to fight for access.
• Rare cancers like Henderson's often lack standard treatments and face reimbursement challenges because insurers rely on FDA labels and guidelines, which frequently lag behind advances in genomic testing and precision medicine.
• Despite advocacy efforts, including public appeals and eventual drug donation from AstraZeneca, Henderson's condition rapidly worsened, and he passed away after nearly two months on Lynparza, highlighting the urgent need for faster access to innovative therapies for rare cancer patients.
• Experts emphasize that as genomic profiling becomes more common, insurance policies must adapt to support personalized treatments, but current clinical trials and coverage frameworks often exclude rare brain tumors, limiting patient options.